Study Category of Trial Enrollment Status
A5128: US Genomic Sampling
Designed to develop a standard operating procedure to establish a storage bank for specimens for future HIV DNA analyses.
Non-Interventional Active, Not Recruiting
A5243: Non-US Genomic Sampling
Collecting blood and saliva samples from former and current ACTG study participants for future HIV-related genetic testing.
Non-Interventional Open and Enrolling
A5300B/I2003B:Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Participants (PHOENIx)
This trial is in household contacts (HHC) at high risk for developing multidrug resistant tuberculosis (MDR-TB) which is an infection that does not get better with standard treatment for TB.
Treatment Experienced Open and Enrolling
A5312: The Early Bactericidal Activity of High Dose or Standard Dose Isoniazid among adult Participants with Isoniazid-Resistant or Drug Sensitive Tuberculosis
This study is for participants who have pulmonary tuberculosis (TB), a bacterial infection in their lungs.
Tuberculosis Open and Enrolling
A5321: Decay of HIV-1 Reservoirs in Participants on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) Study
Studies differences and changes over time in HIV reservoirs (groups of HIV infected cells that ’hide’ from anti-HIV medications).
Treatment Experienced Open and Enrolling
A5322: Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging, HIV Infection and Inflammation (HAILO)
You are being asked to take part in this research study because you are infected with HIV, the virus that causes AIDS, and were previously followed in the ALLRT (A5001) study and are 40 years of age or older.
Treatment Experienced Closed to Accrual
A5332: REPRIEVE Trial
In this study, people between the ages of 40 and 75 with HIV will be randomized (like flipping a coin) to take the pill pitavastatin OR a placebo (non-active pill) to see if pitavastatin can help prevent heart disease and death in people who are taking HIV medication.
Treatment Experienced Closed to Accrual
A5343: A Trial of the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, among Participants Taking Multidrug Treatment for Drug-Resistant Pulmonary Tuberculosis
This is a randomized study, which means, by chance, you will be in one of three groups.
Treatment ExperiencedTuberculosis Closed to Accrual
A5354: Early ART in Acute HIV
Will evaluate whether starting antiretroviral drugs very early in HIV infection will limit the virus from getting into hidden areas of the body (reservoirs) and change how the immune system helps to control the virus.
Treatment Naïve Closed to Accrual
A5355: Phase II, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®) in Adults with Both Human Immunodeficiency Virus (HIV)-1 and CMV Who Are on Potent Combination ART with Conserved Immune Function
Brief Background and Description: Since the early days of the HIV epidemic cytomegalovirus (CMV) has been one of the most common and devastating opportunistic infections (OIs) experienced by people with HIV.
Treatment Experienced Open and Enrolling
A5357: A Study of Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) to Maintain Viral Suppression in Adults Living with HIV-1
This study is for people with HIV who have an undetectable viral load.
Treatment Experienced Open and Enrolling
A5359: The LATITUDE Study
Brief Description: This study will compare Long-Acting (LA) Injectable Antiretroviral Therapy (ART) to standard of care (SOC) oral ART in previously non-adherent PLWH.
Treatment Experienced Open and Enrolling
A5361s: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Aging with HIV may be associated with an earlier development of frailty (weakness) or disability, including difficulties in tests of strength or walking speed.
Treatment Experienced Closed to Accrual
A5364: A Phase I, Open-Label Study of the Safety and Ability of Broadly Neutralizing Antibodies 3BNC117-LS and 10-1074-LS in Combination to Durably Prevent Viral Relapse During a Monitored Analytical Treatment Interruption
ACTG A5364: A Phase I, Open-Label Study of the Safety and Ability of Broadly Neutralizing Antibodies 3BNC117-LS and 10-1074-LS in Combinatio...
Treatment Experienced Open and Enrolling
A5366: Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation with Histone Deacetylase Inhibitors
While antiretrovirals known as ARV’s (group of medicines used to treat HIV) have provided very effective treatment of HIV, cure of HIV from the body has not been possible.
Women Closed to Accrual
A5368:Anti-PD-1 Antibody in HBV Infected on Suppressive Antiviral Therapy
“Safety and Immunotherapeutic Activity of Cemiplimab in Participants with HBV on Suppressive Antiviral Therapy: A Phase I/II Ascending Multiple Dose Study” Brief Description: Scientists are looking at ways to cure Hepatitis B (HBV).
Treatment Experienced Open and Enrolling
A5371: A Single-Arm, Open-Label, Pilot Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome with Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
Short Title: The Slim Liver Study Brief Description: About 30-40% of people living with HIV have a condition called NAFLD, or non-alcoholic fatty liver disease.
Hepatitis Open and Enrolling
A5372: Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals (RPT-DTG PK Study)
The purpose of this research study is see if taking medications to prevent tuberculosis (TB) affect the drug levels in blood of a commonly used HIV medication called dolutegravir (DTG) and if an extra dose of DTG is needed during this TB preventive treatment.
Tuberculosis Open and Enrolling
A5377: Tri-specific Antibody
The first study of a broadly neutralizing antibody called SAR441236 in humans, will determine if an infusion is safe and tolerable and will measure the amount of SAR441236 in the blood over time.
Treatment Experienced Open and Enrolling
A5379: B-Enhancement of HBV vaccination in persons living with HIV (BEe-HIVe): Evaluation of HEPLISAV-B
A5379 is a study looking at hepatitis B vaccination in adults living with HIV.
Hepatitis Open and Enrolling
A5380: Glecaprevir/pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)
This is a study to treat participants, with or without HIV, who are found to have been recently infected with the Hepatitis C virus (HCV).
Hepatitis Open and Enrolling
A5381: Observational Cohort to Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of Tenofovir-Lamivudine-Dolutegravir (TLD) for First- or Second-Line ART
This is a study for people who have HIV and qualify to switch to or receive Dolutegravir containing antiretroviral therapy (ART, group of medicine used to treat HIV).
Treatment Experienced Open and Enrolling
A5386: N-803 with or without bNAbs for HIV-1 control in participants living with HIV-1 on suppressive ART
Full Title: A Phase 1 Clinical Trial of the Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) with and without Combination B...
Treatment Experienced Open and Enrolling
A5391: Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)
ACTG A5391: Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)   Treatment Category:  Treatm...
Treatment Experienced Open and Enrolling
A5392: Pharmacokinetic Interactions of Etonogestrel (ENG) Subdermal Implants with Long-Acting (LA) Cabotegravir (CAB-LA) and LA Rilpivirine (RPV-LA) (CARLA) in Participants of Reproductive Potential
ACTG A5392: Pharmacokinetic Interactions of Etonogestrel (ENG) Subdermal Implants with Long-Acting (LA) Cabotegravir (CAB-LA) and LA Rilpivirine (RPV-LA) (CARLA) in Participants of Reproductive Potential   Treatment Category: Treatment Experienced   Study Description The Etonogestrel (ENG) subdermal implant is used for birth control.
A5401: ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies
Study Description: A master protocol to evaluate the safety and efficacy of investigational agents for the treatment of symptomatic non-hospitalized adults with COVID-19.
COVID-19 Open and Enrolling
A5404: SARS-CoV-2 Immune Responses after COVID-19 Therapy and Vaccine
Right now there is no medicine proven to treat COVID-19 in people who are not sick enough to be hospitalized.
COVID-19 Open and Enrolling
A5418:Study of Tecovirimat for Human Monkeypox Virus (STOMP)
ACTG A5418: A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Monk...
Non-Interventional Open and Enrolling
ACTG A5362: A Phase IIc Trial of Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study
Study Description A5362 is a study for people with pulmonary tuberculosis (TB) without evidence of resistance to the TB drugs isoniazid (INH) or rifampin (RIF).
Treatment Experienced Open and Enrolling
ACTG A5383: Randomized, Controlled Trial to Evaluate the Anti-inflammatory Efficacy of Letermovir (Prevymis) in Adults with Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive ART and Its Effect on Chronic Inflammation, HIV Persistence, and Other Clinical Outcomes (ELICIT)
Brief Description: This study will include 180 participants.
Treatment Experienced Open and Enrolling